Hookipa Pharma Net Income
| HOOK Stock | USD 1.02 0.03 2.86% |
As of the 10th of February, Hookipa Pharma retains the Risk Adjusted Performance of 0.114, downside deviation of 2.03, and Market Risk Adjusted Performance of (0.37). Hookipa Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Hookipa Pharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 1.9077 | Revenue | Earnings Share (4.83) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -39.2 M | -41.1 M | |
| Net Loss | -58.4 M | -61.3 M | |
| Net Loss | -39.2 M | -41.1 M | |
| Net Loss | (3.12) | (3.28) | |
| Net Income Per E B T | 1.15 | 1.10 |
Hookipa | Net Income | Build AI portfolio with Hookipa Stock |
Historical Net Income data for Hookipa Pharma serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Hookipa Pharma represents a compelling investment opportunity.
Latest Hookipa Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Hookipa Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Hookipa Pharma financial statement analysis. It represents the amount of money remaining after all of Hookipa Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Hookipa Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hookipa Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (43.5 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Hookipa Net Income Regression Statistics
| Arithmetic Mean | (31,301,531) | |
| Coefficient Of Variation | (75.56) | |
| Mean Deviation | 19,257,974 | |
| Median | (16,237,000) | |
| Standard Deviation | 23,652,192 | |
| Sample Variance | 559.4T | |
| Range | 68.9M | |
| R-Value | (0.73) | |
| Mean Square Error | 275T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (3,439,139) | |
| Total Sum of Squares | 8950.8T |
Hookipa Net Income History
Other Fundumenentals of Hookipa Pharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Hookipa Pharma Net Income component correlations
Hookipa Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Hookipa Pharma is extremely important. It helps to project a fair market value of Hookipa Stock properly, considering its historical fundamentals such as Net Income. Since Hookipa Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hookipa Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hookipa Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. Market participants price Hookipa higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Hookipa Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.83) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
Investors evaluate Hookipa Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Hookipa Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Hookipa Pharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Hookipa Pharma's market price signifies the transaction level at which participants voluntarily complete trades.
Hookipa Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Hookipa Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Hookipa Pharma.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Hookipa Pharma on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Hookipa Pharma or generate 0.0% return on investment in Hookipa Pharma over 90 days. Hookipa Pharma is related to or competes with ImmunoCellular Therapeutics, Devonian Health, and Propanc Biopharma,. HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseas... More
Hookipa Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Hookipa Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Hookipa Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.03 | |||
| Information Ratio | 0.0797 | |||
| Maximum Drawdown | 7.38 | |||
| Value At Risk | (2.86) | |||
| Potential Upside | 3.45 |
Hookipa Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hookipa Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Hookipa Pharma's standard deviation. In reality, there are many statistical measures that can use Hookipa Pharma historical prices to predict the future Hookipa Pharma's volatility.| Risk Adjusted Performance | 0.114 | |||
| Jensen Alpha | 0.2828 | |||
| Total Risk Alpha | 0.0345 | |||
| Sortino Ratio | 0.0695 | |||
| Treynor Ratio | (0.38) |
Hookipa Pharma February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.114 | |||
| Market Risk Adjusted Performance | (0.37) | |||
| Mean Deviation | 1.26 | |||
| Semi Deviation | 1.21 | |||
| Downside Deviation | 2.03 | |||
| Coefficient Of Variation | 738.96 | |||
| Standard Deviation | 1.77 | |||
| Variance | 3.12 | |||
| Information Ratio | 0.0797 | |||
| Jensen Alpha | 0.2828 | |||
| Total Risk Alpha | 0.0345 | |||
| Sortino Ratio | 0.0695 | |||
| Treynor Ratio | (0.38) | |||
| Maximum Drawdown | 7.38 | |||
| Value At Risk | (2.86) | |||
| Potential Upside | 3.45 | |||
| Downside Variance | 4.1 | |||
| Semi Variance | 1.46 | |||
| Expected Short fall | (1.97) | |||
| Skewness | 0.5997 | |||
| Kurtosis | 1.74 |
Hookipa Pharma Backtested Returns
Hookipa Pharma appears to be risky, given 3 months investment horizon. Hookipa Pharma holds Efficiency (Sharpe) Ratio of 0.16, which attests that the entity had a 0.16 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Hookipa Pharma, which you can use to evaluate the volatility of the firm. Please utilize Hookipa Pharma's Risk Adjusted Performance of 0.114, market risk adjusted performance of (0.37), and Downside Deviation of 2.03 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Hookipa Pharma holds a performance score of 12. The company retains a Market Volatility (i.e., Beta) of -0.61, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Hookipa Pharma are expected to decrease at a much lower rate. During the bear market, Hookipa Pharma is likely to outperform the market. Please check Hookipa Pharma's rate of daily change, period momentum indicator, as well as the relationship between the expected short fall and maximum drawdown , to make a quick decision on whether Hookipa Pharma's current trending patterns will revert.
Auto-correlation | 0.09 |
Virtually no predictability
Hookipa Pharma has virtually no predictability. Overlapping area represents the amount of predictability between Hookipa Pharma time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Hookipa Pharma price movement. The serial correlation of 0.09 indicates that less than 9.0% of current Hookipa Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.09 | |
| Spearman Rank Test | 0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Hookipa Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Hookipa Pharma reported net income of (43.5 Million). This is 112.75% lower than that of the Biotechnology sector and 162.11% lower than that of the Health Care industry. The net income for all United States stocks is 107.62% higher than that of the company.
Hookipa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hookipa Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hookipa Pharma could also be used in its relative valuation, which is a method of valuing Hookipa Pharma by comparing valuation metrics of similar companies.Hookipa Pharma is currently under evaluation in net income category among its peers.
Hookipa Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hookipa Pharma from analyzing Hookipa Pharma's financial statements. These drivers represent accounts that assess Hookipa Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hookipa Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 76.5M | 53.1M | 76.6M | 25.2M | 29.0M | 27.5M | |
| Enterprise Value | 21.2M | (53.9M) | (34.0M) | (13.6M) | (15.6M) | (14.9M) |
Hookipa Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Hookipa Pharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Hookipa Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Hookipa Pharma's value.| Shares | State Street Corp | 2025-06-30 | 17 K | Northern Trust Corp | 2025-06-30 | 15.7 K | Blackrock Inc | 2025-06-30 | 12.2 K | Boothbay Fund Management, Llc | 2025-06-30 | 11.7 K | Tower Research Capital Llc | 2025-06-30 | 3.5 K | Jpmorgan Chase & Co | 2025-06-30 | 815 | Advisor Group Holdings, Inc. | 2025-06-30 | 500 | Bank Of America Corp | 2025-06-30 | 481 | Simplex Trading, Llc | 2025-06-30 | 341 | Baker Bros Advisors Lp | 2025-06-30 | 812.8 K | Siren, L.l.c. | 2025-06-30 | 566.6 K |
Hookipa Fundamentals
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (8.85) % | ||||
| Current Valuation | (20.74 M) | ||||
| Shares Outstanding | 9.93 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 12.16 % | ||||
| Number Of Shares Shorted | 35.8 K | ||||
| Price To Earning | 12.06 X | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 1.38 X | ||||
| Revenue | 43.95 M | ||||
| Gross Profit | (50.47 M) | ||||
| EBITDA | (40.85 M) | ||||
| Net Income | (43.5 M) | ||||
| Cash And Equivalents | 117.92 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 875 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 5.48 X | ||||
| Book Value Per Share | 2.71 X | ||||
| Cash Flow From Operations | (76.98 M) | ||||
| Short Ratio | 0.57 X | ||||
| Earnings Per Share | (4.83) X | ||||
| Price To Earnings To Growth | (0.19) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 12.95 M | ||||
| Total Asset | 82.55 M | ||||
| Retained Earnings | (412.76 M) | ||||
| Working Capital | 56.01 M | ||||
| Current Asset | 26.61 M | ||||
| Current Liabilities | 25.01 M | ||||
| Net Asset | 82.55 M |
About Hookipa Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hookipa Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hookipa Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hookipa Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. Market participants price Hookipa higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Hookipa Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.83) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
Investors evaluate Hookipa Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Hookipa Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Hookipa Pharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Hookipa Pharma's market price signifies the transaction level at which participants voluntarily complete trades.